Tigermed Reports 2024 Interim Results
HANGZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading provider of clinical research solutions...
- Supported exchanges /
- F /
- 5HZ1.F
HANGZHOU TIGERMED CO. H 1 (5HZ1 F) stock market data APIs
€4.12
0.14(3.5%)
as of October 30, 2024
Price chart is built with Anychart
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. It also provides product market research, product marketing strategy, product finalization, product verification, registration strategy planning, marketing application, post-marketing supports, and product upgrade services. In addition, the company offers medical imaging, pharmacovigilance, medical translation, quality assurance, GMP consulting, central laboratories, functional services, EDC system, and call center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
HANGZHOU TIGERMED CO. H 1 Financial Data Overview
| 3.98 | |
| 4.12 | |
| - | |
| 4.12 | |
| 3.98 | |
| 1.9339-5.1 | |
| 6 233 M | |
| 23.4118 | |
| 123 M | |
| 6 801 M | |
| 0.0162 | |
| 0.844 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'5HZ1',
Type:
'Common Stock',
Name:
'HANGZHOU TIGERMED CO. H 1',
Exchange:
'F',
CurrencyCode:
'EUR',
CurrencyName:
'Euro',
CurrencySymbol:
'€',
CountryName:
'Germany',
CountryISO:
'DE',
OpenFigi:
NULL,
ISIN:
'CNE1000040M1',
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Diagnostics & Research',
}
HANGZHOU TIGERMED CO. H 1 Fundamental Data is available in our Financial Data APIs
- Net Revenue 6 801 M
- EBITDA 1 616 M
- Earnings Per Share 0.17
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get HANGZHOU TIGERMED CO. H 1 Earnings via APIs
- Latest Release 2024-10-29
- EPS/Forecast NaN
Get HANGZHOU TIGERMED CO. H 1 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get HANGZHOU TIGERMED CO. H 1 latest news via APIs
Nasdaq Heads Toward Correction After Weak Jobs Report
The stock market’s summer swoon intensified after a disappointing jobs report renewed worries about slowing growth and sparked a broad-based selloff. Continue reading View comments
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
